Video content above is prompted by the following: 4. How do the treatment options evolve as a child ages? a. FDA labeling (dupilumab ≥ 6 months, lebrikizumab ≥ 12 years, tralokinumab ≥ 12 years, ...

LIB Therapeutics has announced that the FDA has accepted its biologics license application (BLA) for lerodalcibep, a treatment designed to lower low-density lipoprotein cholesterol (LDL-C) in patients ...

Panelists discuss the role of newer agents, including biologics/monoclonal antibodies (dupilumab, tralokinumab, lebrikizumab) and Janus kinase (JAK) inhibitors (abrocitinib, baricitinib, upadacitinib) ...

New research has identified novel rhinoconjunctivitis phenotypes in children with asthma which may not be allergy-driven, prompting the need for more research to better understand the pathology of ...

Colleen Sloan, PA-C, RDN, discussed how the 5 senses can affect a child's appetite, as well as how to use food play to get children to try new foods. Imagine biting into a crisp apple, only to find it ...

Panelists discuss the 2023 American Academy of Allergy, Asthma & Immunology/ American College of Allergy, Asthma & Immunology (AAAAI/ACAAI) Joint Task Force guidelines, highlighting treatment options ...

In this discussion, leading experts weigh in on the importance of scientific integrity, proactive advocacy, and the crucial role of vaccinations in pediatric health. As the landscape of pediatric ...

Panelists discuss the goals of treating atopic dermatitis, focusing on symptom control and quality of life, with treatment differing for children and adults, and emphasize using assessment tools such ...

The investigational biologic targets the interleukin-2 receptor complex in the body in order to stimulate proliferation of inhibitory immune cells. Rezpegaldesleukin (Rezpeg; Nektar Therapeutics) has ...

The primary and all key secondary endpoints were met compared to cream vehicle in the phase 3 DELTA TEEN trial. LEO Pharma A/S has reported positive phase 3 data for delgocitinib (Anzupgo) 20 mg /g ...

Navigating the ever-evolving landscape of pediatric care means staying ahead of clinical developments, regulatory shifts, and therapeutic breakthroughs—each with the potential to reshape how we ...

Cyclo Therapeutics has enrolled 10 patients in a single-arm sub-study treating newborns to 3 years of age, evaluating the Trappsol Cyclo in the youngest subsets. Trappsol Cyclo from Cyclo Therapeutics ...